Loading...
Loading...
RDHL| Name | Value |
|---|---|
| Revenues | 18.2M |
| Cost of Revenue | 8.0M |
| Gross Profit | 10.2M |
| Operating Expense | 23.4M |
| Operating I/L | -13.2M |
| Other Income/Expense | -3.9M |
| Interest Income | 0.0M |
| Pretax | -17.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -17.1M |
RedHill Biopharma Ltd. is a specialty biopharmaceutical company that focuses on gastrointestinal and infectious diseases. The company's revenue is primarily generated through the promotion of gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for Helicobacter pylori infection, and Aemcolo for travelers' diarrhea. Additionally, the company's late-stage investigational development programs include RHB-204 for pulmonary nontuberculous mycobacteria infections, opaganib (Yeliva) for SARS-CoV-2 severe COVID-19 pneumonia and cholangiocarcinoma, RHB-107 for COVID-19 and cholangiocarcinoma, RHB-104 for Crohn's disease, RHB-102 (Bekinda) for acute gastroenteritis and gastritis, and RHB-106 for bowel preparation.
